Research Highlight | Published:

TARGETED THERAPIES

Redefining KRAS activation

Nature Reviews Clinical Oncologyvolume 15page532 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original articles

    1. Moll, H. P. et al. Afatinib restrains K-RAS–driven lung tumorigenesis. Sci. Transl Med. 10, eaao2301 (2018)

    2. Kruspig, B. et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci. Transl Med. 10, eaao2565 (2018)

    Download references

    Author information

    Affiliations

    1. Nature Reviews Clinical Oncology

      • Diana Romero

    Authors

    1. Search for Diana Romero in:

    Corresponding author

    Correspondence to Diana Romero.

    About this article

    Publication history

    Published

    DOI

    https://doi.org/10.1038/s41571-018-0068-1

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing